Autologous immunotherapies have evolved in recent years to bring breakthrough treatments to the market. However, the complexity of the production process often results in extended timelines and high manufacturing costs, limiting the scalability and application across therapeutic indications. Therefore, cell therapy providers continue to make new investments to develop standardized and optimized scale-out strategies while balancing the customized processes for each patient treatment.
In this webinar, Catalent presents a clinical-to-commercial perspective on autologous therapies. Professor Gerhard Bauer will discuss the current challenges associated with autologous therapies and Dr. James Crutchley will speak to the various solutions available for commercial scale-up of advanced therapeutics.
Our expert panel will provide insight into:
- Challenges, advantages and disadvantages of several systems that are currently available for manufacturing of these advanced therapies
- Manufacturing by Design Methodology developed by Catalent to deliver process efficiencies and scalability
- How to achieve economies of scale by optimizing across the manufacturing supply chain